The iPhone to Skip?

Join Pete Najarian and Marc LoPresti on today's episode of Rebel's Edge as they discuss stocks including Apple failing to impress with the iPhone 16, Oracle ripping to the upside, and both Ascendis Pharma and Nuvalent showing promise in biotech. Gain a deeper understanding of these stocks as Pete and Marc share their perspectives, potential growth prospects, and market predictions. They also talk about Olympic ratings and whether NFL teams should play rookie QBs. Stay on the cutting edge with Rebel's Edge. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.